AU2014262450A1 - Lipid scavenging in Ras cancers - Google Patents

Lipid scavenging in Ras cancers Download PDF

Info

Publication number
AU2014262450A1
AU2014262450A1 AU2014262450A AU2014262450A AU2014262450A1 AU 2014262450 A1 AU2014262450 A1 AU 2014262450A1 AU 2014262450 A AU2014262450 A AU 2014262450A AU 2014262450 A AU2014262450 A AU 2014262450A AU 2014262450 A1 AU2014262450 A1 AU 2014262450A1
Authority
AU
Australia
Prior art keywords
fatty acids
weeks
ras
lipid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014262450A
Other languages
English (en)
Inventor
Justin CROSS
Jurre KAMPHORST
Joshua Rabinowitz
Craig Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Memorial Sloan Kettering Cancer Center
Original Assignee
Princeton University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University, Memorial Sloan Kettering Cancer Center filed Critical Princeton University
Publication of AU2014262450A1 publication Critical patent/AU2014262450A1/en
Priority to AU2018201800A priority Critical patent/AU2018201800C1/en
Priority to AU2021200360A priority patent/AU2021200360A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014262450A 2013-05-10 2014-05-09 Lipid scavenging in Ras cancers Abandoned AU2014262450A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018201800A AU2018201800C1 (en) 2013-05-10 2018-03-14 Lipid scavenging in Ras cancers
AU2021200360A AU2021200360A1 (en) 2013-05-10 2021-01-20 Lipid scavenging in Ras cancers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822095P 2013-05-10 2013-05-10
US61/822,095 2013-05-10
PCT/US2014/037514 WO2014183047A1 (en) 2013-05-10 2014-05-09 Lipid scavenging in ras cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018201800A Division AU2018201800C1 (en) 2013-05-10 2018-03-14 Lipid scavenging in Ras cancers

Publications (1)

Publication Number Publication Date
AU2014262450A1 true AU2014262450A1 (en) 2015-12-03

Family

ID=51867773

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014262450A Abandoned AU2014262450A1 (en) 2013-05-10 2014-05-09 Lipid scavenging in Ras cancers
AU2018201800A Active AU2018201800C1 (en) 2013-05-10 2018-03-14 Lipid scavenging in Ras cancers
AU2021200360A Abandoned AU2021200360A1 (en) 2013-05-10 2021-01-20 Lipid scavenging in Ras cancers

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018201800A Active AU2018201800C1 (en) 2013-05-10 2018-03-14 Lipid scavenging in Ras cancers
AU2021200360A Abandoned AU2021200360A1 (en) 2013-05-10 2021-01-20 Lipid scavenging in Ras cancers

Country Status (7)

Country Link
US (2) US10130600B2 (enExample)
EP (1) EP2993980B1 (enExample)
JP (2) JP6533519B2 (enExample)
AU (3) AU2014262450A1 (enExample)
CA (2) CA2912052C (enExample)
IL (2) IL242492B (enExample)
WO (1) WO2014183047A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
WO2014186036A1 (en) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP2993980B1 (en) 2013-05-10 2023-11-01 Memorial Sloan Kettering Cancer Center Lipid scavenging in ras cancers
US11369588B2 (en) 2014-03-20 2022-06-28 The Trustees Of Princeton University NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
AU2018310987A1 (en) 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509470A (ja) * 1992-07-24 1995-10-19 ザ・ジョーンズ・ホプキンス・ユニバーシティ がんの治療に脂肪酸合成阻害剤を用いる方法
US6156504A (en) 1996-03-15 2000-12-05 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process
CA2519773C (en) 2003-03-27 2014-02-18 Kengo Akimoto Lipid-improving agent and composition containing lipid-improving agent
US8092839B2 (en) * 2004-12-13 2012-01-10 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
US8652508B2 (en) * 2007-05-25 2014-02-18 Children's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
US20100129430A1 (en) * 2008-11-24 2010-05-27 Stavroula Sofou Liposome drug carriers with ph-sensitivity
TWI629992B (zh) 2011-05-27 2018-07-21 明治股份有限公司 用於預防以及／或者改善癌症引起的非可逆性的代謝紊亂的組合物
RS56394B1 (sr) * 2011-06-15 2017-12-29 Stable Solutions Llc Terapeutska primena parenteralnog kril ulja
EP2993980B1 (en) 2013-05-10 2023-11-01 Memorial Sloan Kettering Cancer Center Lipid scavenging in ras cancers

Also Published As

Publication number Publication date
EP2993980A1 (en) 2016-03-16
IL282229A (en) 2021-05-31
IL242492B (en) 2021-04-29
AU2018201800B2 (en) 2020-10-22
US20160120832A1 (en) 2016-05-05
US20190046489A1 (en) 2019-02-14
CA2912052C (en) 2021-12-14
EP2993980A4 (en) 2017-04-19
IL282229B1 (en) 2023-01-01
CA3136947C (en) 2023-08-08
WO2014183047A1 (en) 2014-11-13
JP6533519B2 (ja) 2019-06-19
JP6970709B2 (ja) 2021-11-24
AU2018201800C1 (en) 2021-04-22
AU2018201800A1 (en) 2018-04-05
AU2021200360A1 (en) 2021-03-18
JP2016521286A (ja) 2016-07-21
JP2019147836A (ja) 2019-09-05
US10772862B2 (en) 2020-09-15
CA2912052A1 (en) 2014-11-13
IL282229B2 (en) 2023-05-01
EP2993980B1 (en) 2023-11-01
CA3136947A1 (en) 2014-11-13
US10130600B2 (en) 2018-11-20

Similar Documents

Publication Publication Date Title
US10772862B2 (en) Lipid scavenging in Ras cancers
Nan et al. Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets
Ma et al. BCAA–BCKA axis regulates WAT browning through acetylation of PRDM16
Kang et al. Deficiency of BCAT2-mediated branched-chain amino acid catabolism promotes colorectal cancer development
Bernfeld et al. Phospholipase D–dependent mTOR complex 1 (mTORC1) activation by glutamine
Peng et al. KHK-A promotes fructose-dependent colorectal cancer liver metastasis by facilitating the phosphorylation and translocation of PKM2
Huang et al. CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein
Zhao et al. Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer
US20100022495A1 (en) Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
Duan et al. The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer
Wang et al. Acid-sensing ion channel 1: potential therapeutic target for tumor
Zhang et al. Alcoholic Setdb1 suppression promotes hepatosteatosis in mice by strengthening Plin2
Huang et al. Enhancement of PPARα-inhibited leucine metabolism-stimulated β-casein synthesis and fatty acid synthesis in primary bovine mammary epithelial cells
Hashimoto et al. Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma
CN110787296A (zh) 一种用于预防或治疗胰腺癌的药物组合物及检测胰腺癌的试剂盒
Ding et al. Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets
Esperança-Martins et al. Sarcoma Metabolomics: Current Horizons and Future Perspectives. Cells. 2021; 10: 1432
Schoonjans Tumor microenvironment involvement in the metabolic reprogramming induced by the PDK inhibitor dichloroacetate
Li et al. PPDPF promotes esophageal squamous cell carcinoma progression by blocking PCCA binding to PCCB and inhibiting methionine catabolism
Lv et al. LGR5/mTORC2 axis regulates cellular metabolic plasticity to maintain tumorigenesis in hepatocellular carcinoma
Han et al. Cancer IDO1‐Mediated Tryptophan–Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration
Al-Asadi Preventing and Treating Hepatic Metastases of Colon and Pancreatic Cancers by Targeting Cancer Cell Metabolism
CN121221774A (zh) 一种基于dgat1靶点的胰腺癌免疫治疗药物及应用
Tseng et al. Transketolase Regulates the Metabolic Switch to Control Breast Cancer Cell Metastasis via the a-Ketoglutarate Signaling Pathway
Nakamura et al. Su1250 Glucagon-Like Peptide-1 Does Not Enhance Inflammatory Responses in Pancreatic Stellate Cells, but Induces Cell Proliferation via ERK Pathway

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted